AcrobiosystemsLtd Past Earnings Performance
Past criteria checks 1/6
AcrobiosystemsLtd has been growing earnings at an average annual rate of 28.7%, while the Biotechs industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 29.4% per year. AcrobiosystemsLtd's return on equity is 6.1%, and it has net margins of 31.1%.
Key information
28.7%
Earnings growth rate
0.3%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 29.4% |
| Return on equity | 6.1% |
| Net Margin | 31.1% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How AcrobiosystemsLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 534 | 166 | 241 | 120 |
| 30 Jun 23 | 514 | 186 | 226 | 124 |
| 31 Mar 23 | 497 | 195 | 204 | 120 |
| 31 Dec 22 | 474 | 204 | 184 | 114 |
| 30 Sep 22 | 461 | 219 | 169 | 107 |
| 30 Jun 22 | 438 | 211 | 146 | 84 |
| 31 Mar 22 | 410 | 187 | 131 | 70 |
| 01 Jan 22 | 385 | 174 | 117 | 60 |
| 30 Sep 21 | 351 | 159 | 87 | 49 |
| 30 Jun 21 | 322 | 146 | 73 | 44 |
| 31 Mar 21 | 286 | 135 | 64 | 37 |
| 31 Dec 20 | 246 | 116 | 57 | 31 |
| 31 Dec 19 | 103 | 11 | 57 | 20 |
| 31 Dec 18 | 70 | 11 | 34 | 17 |
| 31 Dec 17 | 47 | 7 | 25 | 10 |
Quality Earnings: 301080 has a high level of non-cash earnings.
Growing Profit Margin: 301080's current net profit margins (31.1%) are lower than last year (47.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301080's earnings have grown significantly by 28.7% per year over the past 5 years.
Accelerating Growth: 301080's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301080 had negative earnings growth (-24%) over the past year, making it difficult to compare to the Biotechs industry average (-3.9%).
Return on Equity
High ROE: 301080's Return on Equity (6.1%) is considered low.